Over 50% of PDGFRA aberrations locate in the extracellular domains in several types of tumors, including glioma and colorectal cancer, suggesting that mutations in the extracellular domain, not only aberrations in the kinase and juxtamembrane domain, are potentially driver aberrations that warrant implementation of targeted therapy. The gene discussed is PDGFRA; the disease is central nervous system cancer.